A COMPARISON OF KU0063794, A DUAL MTORC1 AND MTORC2 INHIBITOR, AND TEMSIROLIMUS IN PRECLINICAL RENAL CELL CARCINOMA MODELS

被引：0
|
作者：
Zhang, Hao
Berel, Dror
Wang, Yanping
Figlin, Robert
Kim, Hyung
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
10.1016/j.juro.2012.02.359
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：E121 / E122
页数：2
相关论文
共 50 条
  • [31] The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2
    Chen, Bo
    Xu, Ming
    Zhang, Hui
    Xu, Ming-zheng
    Wang, Xu-jing
    Tang, Qing-he
    Tang, Jian-ying
    DNA AND CELL BIOLOGY, 2015, 34 (10) : 610 - 617
  • [32] Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax
    Espona-Fiedler, M.
    Soto-Cerrato, V.
    Hosseini, A.
    Lizcano, J. M.
    Guallar, V.
    Quesada, R.
    Gao, T.
    Perez-Tomas, R.
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (04) : 489 - 496
  • [33] Brief Report: The Differential Roles of mTORC1 and mTORC2 in Mesenchymal Stem Cell Differentiation
    Martin, Sally K.
    Fitter, Stephen
    Dutta, Ankit K.
    Matthews, Mary P.
    Walkley, Carl R.
    Hall, Michael N.
    Ruegg, Markus A.
    Gronthos, Stan
    Zannettino, Andrew C. W.
    STEM CELLS, 2015, 33 (04) : 1359 - 1365
  • [34] mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
    Pollizzi, Kristen N.
    Patel, Chirag H.
    Sun, Im-Hong
    Oh, Min-Hee
    Waickman, Adam T.
    Wen, Jiayu
    Delgoffe, Greg M.
    Powell, Jonathan D.
    JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (05): : 2090 - 2108
  • [35] Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth
    Barr, Sharon
    Falcon, Beverly L.
    Ghokale, Prafulla C.
    Chou, Jeyling
    Fogarty, Jennifer
    Depeille, Philippe
    Miglarese, Mark
    Epstein, David M.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [36] Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
    Tasneen, Rokeya
    Mortensen, Deborah S.
    Converse, Paul J.
    Urbanowski, Michael E.
    Upton, Anna
    Fotouhi, Nader
    Nuermberger, Eric
    Hawryluk, Natalie
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (07)
  • [37] Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion
    Eric C. Kauffman
    Martin Lang
    Soroush Rais-Bahrami
    Gopal N. Gupta
    Darmood Wei
    Youfeng Yang
    Carole Sourbier
    Ramaprasad Srinivasan
    BMC Cancer, 19
  • [38] Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion
    Kauffman, Eric C.
    Lang, Martin
    Rais-Bahrami, Soroush
    Gupta, Gopal N.
    Wei, Darmood
    Yang, Youfeng
    Sourbier, Carole
    Srinivasan, Ramaprasad
    BMC CANCER, 2019, 19 (01) : 917
  • [39] Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia
    Kawata, Takahito
    Tada, Kohei
    Kobayashi, Masayuki
    Sakamoto, Takashi
    Takiuchi, Yoko
    Iwai, Fumie
    Sakurada, Maki
    Hishizawa, Masakatsu
    Shirakawa, Kotaro
    Shindo, Keisuke
    Sato, Hironori
    Takaori-Kondo, Akifumi
    CANCER SCIENCE, 2018, 109 (01): : 103 - 111
  • [40] The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
    L Willems
    N Chapuis
    A Puissant
    T T Maciel
    A S Green
    N Jacque
    C Vignon
    S Park
    S Guichard
    O Herault
    A Fricot
    O Hermine
    I C Moura
    P Auberger
    N Ifrah
    F Dreyfus
    D Bonnet
    C Lacombe
    P Mayeux
    D Bouscary
    J Tamburini
    Leukemia, 2012, 26 : 1195 - 1202
12345